Top

Published in:

01-01-2004 | Clinical Commentary

Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients?

Authors: Élie Azoulay, Christophe Delclaux

Published in: Intensive Care Medicine | Issue 1/2004

Abstract

Immunoparalysis, characterised by impairments in neutrophil and monocyte/macrophage function, is common in critically ill patients. The theoretical ability of granulocyte colony-stimulating factor (G-CSF) to improve the functions of both neutrophils and monocytes/macrophages provides a rationale for G-CSF therapy in non-neutropenic critically ill patients with infection or a high risk of nosocomial infection. The expression of the receptors that mediate G-CSF effects in neutrophils and monocytes/macrophages is regulated by bacterial products, cytokines and endogenous G-CSF levels, accounting for the variables effects of G-CSF on the neutrophil functions of critically ill patients. This variability should be taken into account when designing studies on the use of G-CSF in ICU-patients. Studies are still needed to identify the subset of patients who may benefit from G-CSF therapy.

Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 327:99–106CrossRefPubMed

Andres E, Kurtz JE, Perrin AE, Dufour P, Schlienger JL, Maloisel F (2001) Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis. QJM 94:423–428CrossRefPubMed

Boogaerts M, Cavalli F, Cortes-Funes H, Gatell JM, Gianni AM, Khayat D, Levy Y, Link H (1995) Granulocyte growth factors: achieving a consensus. Ann Oncol 6:237–244CrossRefPubMed

Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G (1996) Filgrastim (r-metHuG-CSF): the first 10 years. Blood 88:1907–1929CrossRefPubMed

Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, Vose JM, Kruse S, Dix SP, Morris ME, Armitage JO, Kessinger A (2000) A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 96:80–85CrossRefPubMed

Schmaldienst S, Bekesi G, Deicher R, Franz M, Horl WH, Pohanka E (2000) Recombinant human granulocyte colony-stimulating factor after kidney transplantation: a retrospective analysis to evaluate the benefit or risk of immunostimulation. Transplantation 69:527–531CrossRefPubMed

Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ (2000) Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 18:395–404CrossRefPubMed

Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356:1384–1391CrossRefPubMed

Dale DC, Liles WC, Summer WR, Nelson S (1995) Review: granulocyte colony-stimulating factor—role and relationships in infectious diseases. J Infect Dis 172:1061–1075CrossRefPubMed

10.

Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A (1992) Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80:2012–2020CrossRefPubMed

11.

Basu S, Dunn A, Ward A (2002) G-CSF: function and modes of action (Review). Int J Mol Med 10:3–10PubMed

12.

Hollenstein U, Homoncik M, Stohlawetz PJ, Marsik C, Sieder A, Eichler HG, Jilma B (2000) Endotoxin down-modulates granulocyte colony-stimulating factor receptor (CD114) on human neutrophils. J Infect Dis 182:343–346CrossRefPubMed

13.

Weiss M, Moldawer LL, Schneider EM (1999) Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood 93:425–439CrossRefPubMed

14.

Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T (2000) Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood 95:270–276CrossRefPubMed

15.

Tanaka H, Nishino M, Nakamori Y, Ogura H, Ishikawa K, Shimazu T, Sugimoto H (2001) Granulocyte colony-stimulating factor (G-CSF) stiffens leukocytes but attenuates inflammatory response without lung injury in septic patients. J Trauma 51:1110–1116PubMed

16.

Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W (1997) Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678–681CrossRefPubMed

17.

Stephan F, Yang K, Tankovic J, Soussy CJ, Dhonneur G, Duvaldestin P, Brochard L, Brun-Buisson C, Harf A, Delclaux C (2002) Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 30:315–322CrossRefPubMed

18.

Solberg CO, Hellum KB (1972) Neutrophil granulocyte function in bacterial infections. Lancet 2:727–730CrossRefPubMed

19.

Christou NV, Meakins JL (1979) Neutrophil function in anergic surgical patients: neutrophil adherence and chemotaxis. Ann Surg 190:557–564PubMedCentralCrossRefPubMed

20.

Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM (1991) Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:1747–1754PubMedCentralCrossRefPubMed

21.

Jacobs RF, Kiel DP, Balk RA (1986) Alveolar macrophage function in a canine model of endotoxin-induced lung injury. Am Rev Respir Dis 134:745–751PubMed

22.

Weiss M, Gross-Weege W, Schneider M, Neidhardt H, Liebert S, Mirow N, Wernet P (1995) Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J Crit Care 10:21–26CrossRefPubMed

23.

Weiss M, Gross-Weege W, Harms B, Schneider EM (1996) Filgrastim (RHG-CSF) related modulation of the inflammatory response in patients at risk of sepsis or with sepsis. Cytokine 8:260–265CrossRefPubMed

24.

Gross-Weege W, Weiss M, Schneider M, Wenning M, Harms B, Dumon K, Ohmann C, Roher HD (1997) Safety of a low-dosage Filgrastim (rhG-CSF) treatment in non-neutropenic surgical intensive care patients with an inflammatory process. Intensive Care Med 23:16–22CrossRefPubMed

25.

Gerber A, Struy H, Weiss G, Lippert H, Ansorge S, Schulz HU (2000) Effect of granulocyte colony-stimulating factor treatment on ex vivo neutrophil functions in nonneutropenic surgical intensive care patients. J Interferon Cytokine Res 20:1083–1090CrossRefPubMed

26.

Weiss M, Voglic S, Harms-Schirra B, Lorenz I, Lasch B, Dumon K, Gross-Weege W, Schneider EM (2003) Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission. Intensive Care Med 29:904–914CrossRefPubMed

27.

Yang K, Azoulay E, Attalah L, Zahar JR, Van de Louw A, Cerf C, Soussy CJ, Duvaldestin P, Brochard L, Brun-Buisson C, Harf A, Delclaux C (2003) Bactericidal activity response of blood neutrophils from critically ill patients to in vitro granulocyte colony-stimulating factor stimulation. Intensive Care Med 29:396–402CrossRefPubMed

28.

Nelson S, Belknap SM, Carlson RW, Dale D, DeBoisblanc B, Farkas S, Fotheringham N, Ho H, Marrie T, Movahhed H, Root R, Wilson J (1998) A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. J Infect Dis 178:1075–1080CrossRefPubMed

29.

Fiuza C, Salcedo M, Clemente G, Tellado JM (2002) Granulocyte colony-stimulating factor improves deficient in vitro neutrophil transendothelial migration in patients with advanced liver disease. Clin Diagn Lab Immunol 9:433–439PubMedCentralPubMed

30.

Noursadeghi M, Bickerstaff MC, Herbert J, Moyes D, Cohen J, Pepys MB (2002) Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection. J Immunol 169:913–919CrossRefPubMed

31.

Zhang P, Bagby GJ, Stoltz DA, Summer WR, Nelson S (1999) Granulocyte colony-stimulating factor modulates the pulmonary host response to endotoxin in the absence and presence of acute ethanol intoxication. J Infect Dis 179:1441–1448CrossRefPubMed

32.

Freeman BD, Quezado Z, Zeni F, Natanson C, Danner RL, Banks S, Quezado M, Fitz Y, Bacher J, Eichacker PQ (1997) rG-CSF reduces endotoxemia and improves survival during E. coli pneumonia. J Appl Physiol 83:1467–1475CrossRefPubMed

33.

Smith WS, Sumnicht GE, Sharpe RW, Samuelson D, Millard FE (1995) Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 86:1301–1309CrossRefPubMed

34.

Shirai R, Kadota J, Tomono K, Ogawa K, Iida K, Kawakami K, Kohno S (1997) Protective effect of granulocyte colony-stimulating factor (G-CSF) in a granulocytopenic mouse model of Pseudomonas aeruginosa lung infection through enhanced phagocytosis and killing by alveolar macrophages through priming tumour necrosis factor-alpha (TNF-alpha) production. Clin Exp Immunol 109:73–79PubMedCentralCrossRefPubMed

35.

Nelson S, Summer W, Bagby G, Nakamura C, Stewart L, Lipscomb G, Andresen J (1991) Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis 164:901–906CrossRefPubMed

36.

Hebert JC, O’Reilly M, Gamelli RL (1990) Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg 125:1075–1078CrossRefPubMed

37.

Dallaire F, Ouellet N, Simard M, Bergeron Y, Bergeron MG (2001) Efficacy of recombinant human granulocyte colony-stimulating factor in a murine model of pneumococcal pneumonia: effects of lung inflammation and timing of treatment. J Infect Dis 183:70–77CrossRefPubMed

38.

Chiller T, Farrokhshad K, Brummer E, Stevens DA (2002) Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans. Med Mycol 40:21–26CrossRefPubMed

39.

Patton JH Jr, Lyden SP, Ragsdale DN, Croce MA, Fabian TC, Proctor KG (1998) Granulocyte colony-stimulating factor improves host defense to resuscitated shock and polymicrobial sepsis without provoking generalized neutrophil-mediated damage. J Trauma 44:750–758; discussion 758–759CrossRefPubMed

40.

Abraham E, Stevens P (1992) Effects of granulocyte colony-stimulating factor in modifying mortality from Pseudomonas aeruginosa pneumonia after hemorrhage. Crit Care Med 20:1127–1133CrossRefPubMed

41.

Attalah HL, Azoulay E, Yang K, Lasclos C, Jouault H, Soussy CJ, Guillot T, Brochard L, Brun-Buisson C, Harf A, Delclaux C (2002) Granulocyte colony-stimulating factor enhances host defenses against bacterial pneumonia following peritonitis in nonneutropenic rats. Crit Care Med 30:2107–2114CrossRefPubMed

42.

Quezado Z, Parent C, Karzai W, Depietro M, Natanson C, Hammond W, Danner RL, Cui X, Fitz Y, Banks SM, Gerstenberger E, Eichacker PQ (2001) Acute G-CSF therapy is not protective during lethal E. coli sepsis. Am J Physiol Regul Integr Comp Physiol 281:R1177–1185CrossRefPubMed

43.

DeBoisblanc BP, Mason CM, Andresen J, Logan E, Bear MB, Johnson S, Shellito J, Summer WR, Nelson S (1997) Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia. Respir Med 91:387–394CrossRefPubMed

44.

Nelson S, Heyder AM, Stone J, Bergeron MG, Daugherty S, Peterson G, Fotheringham N, Welch W, Milwee S, Root R (2000) A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 182:970–973CrossRefPubMed

45.

Nelson S (2001) Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 119:419S–425SCrossRefPubMed

46.

Heard SO, Fink MP, Gamelli RL, Solomkin JS, Joshi M, Trask AL, Fabian TC, Hudson LD, Gerold KB, Logan ED (1998) Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group. Crit Care Med 26:748–754CrossRefPubMed

47.

Pettila V, Takkunen O, Varpula T, Markkola A, Porkka K, Valtonen V (2000) Safety of granulocyte colony-stimulating factor (filgrastim) in intubated patients in the intensive care unit: interim analysis of a prospective, placebo-controlled, double-blind study. Crit Care Med 28:3620–3625CrossRefPubMed

48.

Wunderink R, Leeper K Jr, Schein R, Nelson S, DeBoisblanc B, Fotheringham N, Logan E (2001) Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 119:523–529CrossRefPubMed

49.

Meyanci G, Oz H (2001) Combination of granulocyte colony-stimulating factor and antibacterial drugs for the treatment of ventilatory associated nosocomial pneumonia. Middle East J Anesthesiol 16:91–101PubMed

50.

Stephens DP, Fisher DA, Currie BJ (2002) An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J 32:143–148CrossRefPubMed

51.

Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, Vincent JL, Torres A, Rello J, Nelson S (2003) Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 31:367–373CrossRefPubMed

52.

Tate RM, Repine JE (1983) Neutrophils and the adult respiratory distress syndrome. Am Rev Respir Dis 128:552–559CrossRefPubMed

53.

Weiss SJ (1989) Tissue destruction by neutrophils. N Engl J Med 320:365–376CrossRefPubMed

54.

Freeman BD, Correa R, Karzai W, Natanson C, Patterson M, Banks S, Fitz Y, Danner RL, Wilson L, Eichacker PQ (1996) Controlled trials of rG-CSF and CD11b-directed MAb during hyperoxia and E. coli pneumonia in rats. J Appl Physiol 80:2066–2076CrossRefPubMed

55.

Karzai W, von Specht BU, Parent C, Haberstroh J, Wollersen K, Natanson C, Banks SM, Eichacker PQ (1999) G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 159:1377–1382CrossRefPubMed

56.

King J, Deboisblanc BP, Mason CM, Onofrio JM, Lipscomb G, Mercante DE, Summer WR, Nelson S (1995) Effect of granulocyte colony-stimulating factor on acute lung injury in the rat. Am J Respir Crit Care Med 151:302–309CrossRefPubMed

57.

Terashima T, Kanazawa M, Sayama K, Ishizaka A, Urano T, Sakamaki F, Nakamura H, Waki Y, Tasaka S (1994) Granulocyte colony-stimulating factor exacerbates acute lung injury induced by intratracheal endotoxin in guinea pigs. Am J Respir Crit Care Med 149:1295–1303CrossRefPubMed

58.

Azoulay E, Attalah H, Yang K, Jouault H, Schlemmer B, Brun-Buisson C, Brochard L, Harf A, Delclaux C (2002) Exacerbation by granulocyte colony-stimulating factor of prior acute lung injury: implication of neutrophils. Crit Care Med 30:2115–2122CrossRefPubMed

59.

Azoulay E, Attalah H, Yang K, Herigault S, Jouault H, Brun-Buisson C, Brochard L, Harf A, Schlemmer B, Delclaux C (2003) Exacerbation with granulocyte-colony stimulating factor of prior acute lung injury during neutropenia recovery in rats. Crit Care Med 31:157–165CrossRefPubMed

60.

Azoulay E, Attalah H, Harf A, Schlemmer B, Delclaux C (2001) Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest 120:1695–1701CrossRefPubMed

61.

Armstrong WS, Kazanjian P (2001) Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin and interleukin-2. Clin Infect Dis 32:766–773CrossRefPubMed

62.

Dubreuil-Lemaire ML, Gori A, Vittecoq D, Panelatti G, Tharaux F, Palisses R, Gharakhanian S, Rozenbaum W (2000) Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. Eur J Haematol 65:337–343CrossRefPubMed

63.

Keiser P, Rademacher S, Smith JW, Skiest D, Vadde V (1998) Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients. Am J Med 104:48–55CrossRefPubMed

64.

Kuritzkes DR (2000) Neutropenia, neutrophil dysfunction and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis 30:256–260CrossRefPubMed

65.

Gessler P, Kirchmann N, Kientsch-Engel R, Haas N, Lasch P, Kachel W (1993) Serum concentrations of granulocyte colony-stimulating factor in healthy term and preterm neonates and in those with various diseases including bacterial infections. Blood 82:3177–3182CrossRefPubMed

66.

Miura E, Procianoy RS, Bittar C, Miura CS, Miura MS, Mello C, Christensen RD (2001) A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics 107:30–35CrossRefPubMed

67.

De Lalla F, Nicolin R, Lazzarini L (2000) Safety and efficacy of recombinant granulocyte colony-stimulating factor as an adjunctive therapy for Streptococcus pneumoniae meningitis in non-neutropenic adult patients: a pilot study. J Antimicrob Chemother 46:843–846CrossRef

68.

Chantelau E, Kimmerle R (1998) Granulocyte-colony-stimulating factor in diabetic foot infection. Lancet 351:370CrossRefPubMed

69.

De Lalla F, Pellizzer G, Strazzabosco M, Martini Z, Du Jardin G, Lora L, Fabris P, Benedetti P, Erle G (2001) Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 45:1094–1098CrossRef

70.

Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME (1997) Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 350:855–859CrossRefPubMed

71.

Yonem A, Cakir B, Guler S, Azal OO, Corakci A (2001) Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 3:332–337CrossRefPubMed

72.

Rolando N, Clapperton M, Wade J, Wendon J (2000) Administering granulocyte colony-stimulating factor to acute liver failure patients corrects neutrophil defects. Eur J Gastroenterol Hepatol 12:1323–1328CrossRefPubMed

73.

Rolando N, Clapperton M, Wade J, Panetsos G, Mufti G, Williams R (2000) Granulocyte colony-stimulating factor improves function of neutrophils from patients with acute liver failure. Eur J Gastroenterol Hepatol 12:1135–1140CrossRefPubMed

74.

Foster PF, Mital D, Sankary HN, McChesney LP, Marcon J, Koukoulis G, Kociss K, Leurgans S, Whiting JF, Williams JW (1995) The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation 59:1557–1563CrossRefPubMed

75.

Winston DJ, Foster PF, Somberg KA, Busuttil RW, Levy MF, Sheiner PA, Reddy KR, Fotheringham N, Armstrong M, Logan E (1999) Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. Transplantation 68:1298–1304CrossRefPubMed

Title: Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients?
Authors: Élie Azoulay
Christophe Delclaux
Publication date: 01-01-2004
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 1/2004
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-003-2049-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2004

The prognostic value of transcranial Doppler studies in children with moderate and severe head injury

Lessons from a heat wave

The epidemiologist in the intensive care unit

Measurement of lung volume in mechanically ventilated monkeys with an ultrasonic flow meter and the nitrogen washout method

January 2004

Norepinephrine compromises intestinal microvascular perfusion?